

Regimen Reference Order – BRST – fulvestrant

To order this therapy in ARIA, refer to Additional Information below

Planned Course: Until disease progression or unacceptable toxicity (1 cycle = 84 days)

Indication for Use: Breast Cancer Metastatic

CVAD: Not Required

Blood work requirements:

Blood work at provider's discretion; not required to proceed with treatment

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

| Drug | Dose | CCMB Administration Guideline |
|----------------|------|-------------------------------|
| Not Applicable | | |

Treatment Regimen – BRST – fulvestrant

| Drug | Dose | CCMB Administration Guideline |
|---|-------------------------------|---|
| Cycle 1 | | |
| fulvestrant | 500 mg (2 syringes of 250 mg) | Intramuscular into ventrogluteal muscle over 1 to 2 minutes per injection (administer 500 mg dose as two 5 mL IM injections) on Days 1, 15, 29, 57 |
| Cycle 2 and Onwards | | |
| fulvestrant | 500 mg (2 syringes of 250 mg) | Intramuscular into ventrogluteal muscle over 1 to 2 minutes per injection (administer 500 mg dose as two 5 mL IM injections) on Days 1, 29 and 57 |
| fulvestrant available dosage strength: 250 mg per 5mL syringe Classification: Non-Cytotoxic, Hazardous | | |

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

Every clinic visit (at least every 3 months)

- Blood work as per Physician Order

Recommended Support Medications

| Drug | Dose | CCMB Administration Guideline |
|---------------|------|-------------------------------|
| None required | | |

DISCHARGE INSTRUCTIONS

- Not applicable

ADDITIONAL INFORMATION

- The length of the needle provided with fulvestrant is 1.5 inches (38 mm)
- The patient’s body habitus and ventrogluteal fat thickness should be evaluated to ensure the delivery of drug into the muscle
- The preferred site of administration for fulvestrant is into ventrogluteal muscle. Dorsogluteal injections are associated with increased possibility of damaging the sciatic nerve
- fulvestrant should be kept in the refrigerator
- When LHRH agonist therapy is clinically indicated (e.g. for pre or peri-menopausal patients) therapy continues throughout fulvestrant therapy
- **ARIA ordering:** Support protocol is available for fulvestrant under **fulvestrant** in the “Breast Cancer” folder